Lymphoma ASH 2024 Highlights

home / data-dialogue-with-the-oncology-brothers / lymphoma-ash-2024-highlights

Panelists discuss the key findings and emerging treatments for lymphoma presented at the American Society for Hematology Meeting and Exposition (ASH) 2024, focusing on novel therapies, clinical trial results, and their potential impact on current treatment strategies.

Overview of the POLARIX Study

EP. 1: Overview of the POLARIX Study

Rahul Gosain, MD;Rohit Gosain, MD;Pallawi Torka, MD
January 28th 2025

Panelists discuss the findings from the POLARIX study, focusing on the efficacy and safety of polatuzumab vedotin in combination with rituximab and chemotherapy for untreated diffuse large B-cell lymphoma.

Overview of the inMIND Study

EP. 2: Overview of the inMIND Study

Rahul Gosain, MD;Rohit Gosain, MD;Pallawi Torka, MD
January 28th 2025

Panelists discuss the inMIND study, exploring the efficacy and safety of mindetuximab for the treatment of relapsed or refractory non-Hodgkin lymphoma and its potential impact on future therapeutic strategies.

Overview of the TRIANGLE Study

EP. 3: Overview of the TRIANGLE Study

Rahul Gosain, MD;Rohit Gosain, MD;Pallawi Torka, MD
January 28th 2025

Panelists discuss the TRIANGLE study, examining the efficacy and safety of the combination of rituximab, lenalidomide, and chemotherapy in treating high-risk diffuse large B-cell lymphoma and its potential to improve patient outcomes.

Overview of the ENRICH Study

EP. 4: Overview of the ENRICH Study

Rahul Gosain, MD;Rohit Gosain, MD;Pallawi Torka, MD
January 28th 2025

Panelists discuss the ENRICH study, focusing on the efficacy and safety of enzalutamide in combination with standard therapies for metastatic castration-resistant prostate cancer and its potential to improve progression-free survival.